UNSPSC 51384303: Flazalone

This classification denotes a nonsteroidal antiinflammatory drug, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5A1Y43ML91. European Medicines Agency schedules Flazalone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07636MIG. Flazalone generally arises in the molecular formula C19H19F2NO2. The term FLAZALONE is an International Non-Proprietary Name or INN. FLAZALONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

Most nations schedule flazalone under HS 29333999 and SITC 51574. As of Q4 2014, FLAZALONE remains the US FDA Preferred Term for this commodity. Flazalone bears US NLM identifiers UMLS ID C0060451 and NCI Concept Code C80552. SMILES: FC1CCC(C2(O)C(CN(CC2)C)C(=O)C2CCC(F)CC2)CC1.

UNSPSC 51384303 Flazalone is a Commodity code that covers pharmaceutical and pharmaceutical-adjacent products, though recent state and local solicitations show the code being applied to naloxone (an opioid-overdose reversal medication) and drug deactivation systems rather than flazalone specifically. State and local agencies procure naloxone as a public health supply—Seminole County, Florida, for example, seeks 1,900 units annually for quarterly delivery to support community health initiatives—and drug deactivation systems for safe pharmaceutical waste management. The issuing bodies span county health departments and state health commissions; Seminole County and the Texas Health and Human Services Commission represent recent active buyers. The broader pharmaceutical-procurement activity under related UNSPSC classifications shows demand from state cooperative purchasing alliances, including multistate purchasing vehicles that negotiate generic pharmaceuticals and OTC products across member jurisdictions.

Activity appears concentrated in Florida and Texas, with cooperative purchasing extending to multiple states through vehicles such as the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP). Representative recent opportunities include Seminole County's IFB for naloxone and drug deactivation systems (IFB 60459723LAS, due July 26, 2023, for quarterly deliveries), the Texas Health and Human Services Commission's Request for Information on direct-to-manufacturer prescription programs (HHS0017013, posted April 3, 2026), and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products (S1070000015802, due March 26, 2026, with contract effectiveness July 1, 2026). The Seminole County bid requires electronic submission through the county's e-Procurement Portal, includes a two-year initial term with one-year renewal option, and mandates E-Verify compliance and fixed-fee pricing. The MMCAP RFP uses an ePro procurement system, requires cGMP and Drug Supply Chain Security Act compliance, and weighs price competitiveness at 75 percent of evaluation.